Literature DB >> 8765026

A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation.

C Bottino1, S Sivori, M Vitale, C Cantoni, M Falco, D Pende, L Morelli, R Augugliaro, G Semenzato, R Biassoni, L Moretta, A Moretta.   

Abstract

Human natural killer (NK) cells express inhibitory (p58) or activatory (p50) receptors for HLA-C alleles. Here, we describe a novel member of the p58/p50 family that is expressed by a subset of NK cells in about one third of donors. This molecule, termed p50.3, mediates NK cell triggering as revealed by the induction of intracellular free calcium mobilization, cytokine release and cytotoxicity. In addition, anti-p50.3 monoclonal antibody (mAb) induced a selective, strong proliferation of p50.3+ NK cells in peripheral blood lymphocytes. Although p50.3 molecules do not appear to display an obvious HLA class I specificity, they are usually coexpressed with known inhibitory receptors for HLA class I alleles, mAb-mediated cross-linking of these receptors leads to inhibition of the anti-p50.3 mAb-induced NK cell activation and proliferation. Surface p50.3 molecules are glycoproteins of approximately 55-58 kDa which, upon deglycosylation, display a relative molecular mass of 36 kDa, similar to that of deglycosylated (activatory) p50 receptors. Analysis of the two-dimensional peptide maps of the 50.3 molecules revealed a high homology with the other HLA-C-specific p58/p50 receptors. The use of a set of oligodeoxynucleotide primers, previously shown to amplify the activatory (p50) forms of HLA-C-specific receptors, consistently amplified in p50.3+ clones a cDNA sequence termed KKA3. This sequence belongs to the p58/p50 multigene family, that encodes for a transmembrane protein specifically stained by anti-p50.3 mAb in cell transfectants. Similar to p50 molecules, the KKA3-encoded molecules are characterized by two extracellular immunoglobulin-like domains, by the presence of a lysine in the transmembrane region and a short (39 amino acids) cytoplasmic tail which does not contain immune receptor tyrosine-based activation motifs (ITAM)-like sequences.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765026     DOI: 10.1002/eji.1830260823

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Dendritic cell interactions with NK cells from different tissues.

Authors:  Guido Ferlazzo; Christian Münz
Journal:  J Clin Immunol       Date:  2009-03-12       Impact factor: 8.317

2.  Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses.

Authors:  Roberto Biassoni; Elisabetta Ugolotti; Andrea De Maria
Journal:  Self Nonself       Date:  2010-03-06

Review 3.  The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules.

Authors:  M López-Botet; M Carretero; J Pérez-Villar; T Bellón; M Llano; F Navarro
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 4.  DAP12 and KAP10 (DAP10)-novel transmembrane adapter proteins of the CD3zeta family.

Authors:  M J Wilson; J A Lindquist; J Trowsdale
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

5.  Lack of expression of inhibitory KIR3DL1 receptor in patients with natural killer cell-type lymphoproliferative disease of granular lymphocytes.

Authors:  Cristina Gattazzo; Antonella Teramo; Marta Miorin; Elisa Scquizzato; Anna Cabrelle; Mirna Balsamo; Carlo Agostini; Elena Vendrame; Monica Facco; Maria Paola Albergoni; Livio Trentin; Massimo Vitale; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2010-04-21       Impact factor: 9.941

6.  Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002.

Authors:  Steven G E Marsh; Peter Parham; Bo Dupont; Daniel E Geraghty; John Trowsdale; Derek Middleton; Carlos Vilches; Mary Carrington; Campbell Witt; Lisbeth A Guethlein; Heather Shilling; Christian A Garcia; Katharine C Hsu; Hester Wain
Journal:  Immunogenetics       Date:  2003-06-28       Impact factor: 2.846

7.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Authors:  Francois Romagné; Pascale André; Pieter Spee; Stefan Zahn; Nicolas Anfossi; Laurent Gauthier; Marusca Capanni; Loredana Ruggeri; Don M Benson; Bradley W Blaser; Mariella Della Chiesa; Alessandro Moretta; Eric Vivier; Michael A Caligiuri; Andrea Velardi; Nicolai Wagtmann
Journal:  Blood       Date:  2009-06-24       Impact factor: 22.113

8.  Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity.

Authors:  A Pessino; S Sivori; C Bottino; A Malaspina; L Morelli; L Moretta; R Biassoni; A Moretta
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

9.  Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells.

Authors:  C Münz; N Holmes; A King; Y W Loke; M Colonna; H Schild; H G Rammensee
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

10.  KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.

Authors:  Thorsten Graef; Achim K Moesta; Paul J Norman; Laurent Abi-Rached; Luca Vago; Anastazia M Older Aguilar; Michael Gleimer; John A Hammond; Lisbeth A Guethlein; David A Bushnell; Philip J Robinson; Peter Parham
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.